Soluble tumour necrosis factor receptor type II and survival in colorectal cancer

DSpace/Manakin Repository

Soluble tumour necrosis factor receptor type II and survival in colorectal cancer

Citable link to this page

 

 
Title: Soluble tumour necrosis factor receptor type II and survival in colorectal cancer
Author: Babic, Ana; Shah, Sonali M; Song, Mingyang ORCID  0000-0002-1324-0316 ; Wu, Kana; Meyerhardt, Jeffrey A; Ogino, Shuji; Yuan, Chen; Giovannucci, Edward L; Chan, Andrew T; Stampfer, Meir J; Fuchs, Charles S; Ng, Kimmie

Note: Order does not necessarily reflect citation order of authors.

Citation: Babic, A., S. M. Shah, M. Song, K. Wu, J. A. Meyerhardt, S. Ogino, C. Yuan, et al. 2016. “Soluble tumour necrosis factor receptor type II and survival in colorectal cancer.” British Journal of Cancer 114 (9): 995-1002. doi:10.1038/bjc.2016.85. http://dx.doi.org/10.1038/bjc.2016.85.
Full Text & Related Files:
Abstract: Background: Chronic inflammation may play a role in colorectal cancer (CRC) pathogenesis. The relationship between soluble tumour necrosis factor receptor type II (sTNF-RII) and survival among CRC patients is not well defined. Methods: We prospectively evaluated the association between pre-diagnosis plasma levels of sTNF-RII and mortality in 544 CRC patients from the Nurses' Health Study and Health Professionals Follow-Up Study diagnosed from 1990 to 2010. Primary and secondary end points were overall and CRC-specific mortality, respectively. Cox proportional hazards models were used to calculate multivariate hazard ratios for mortality. Results: Higher sTNF-RII levels were significantly associated with increased overall mortality (multivariate HR=1.48, 95% CI 1.02–2.16, P-trend=0.006), but not with CRC-specific mortality (HR=1.23, 95% CI 0.72–2.08, P-trend=0.34). In subgroup analyses, among regular aspirin users, those with higher sTNF-RII levels had an adjusted HR of 0.52 (95% CI 0.20–1.33) for overall mortality compared with those with lower sTNF-RII levels, whereas among nonregular aspirin users the adjusted HR was 2.26 (95% CI 1.23–4.01, P for interaction=0.53). Conclusions: Among CRC patients, higher sTNF-RII levels are associated with a significant increase in overall mortality, but not CRC-specific mortality. The role of inflammation and anti-inflammatory medications in survival of CRC patients warrants further exploration.
Published Version: doi:10.1038/bjc.2016.85
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984918/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630718
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters